We sought to describe tobramycin absorption after aerosol administration to cystic fibrosis
(CF) subjects. Serum tobramycin concentrations were determined by modification of the …

Objectives Tobramycin inhalation solution (TIS; TOBI®) has improved forced expiratory
volume in 1 sec (FEV1) in cystic fibrosis (CF) trials. Using data from the Epidemiologic Study …

Repeated bouts of acute and chronic lung infections are responsible for progressive
pulmonary function decline in individuals with cystic fibrosis (CF), ultimately leading to …

It has been established that inhaled tobramycin has a positive effect on respiratory function
in Pseudomonas-aeruginosa positive patients with cystic fibrosis (CF). In a previous study …

The aerosol performance and delivery characteristics of tobramycin for the treatment of
respiratory infection were evaluated using the Orbital™, a multi-breath, high dose, dry …

Background and aim Chronic infection with Pseudomonas aeruginosa in patients with cystic
fibrosis (CF) causes progressive deterioration in lung function. The purpose of this trial was …

Study objective To determine the effect of long-term suppression of Pseudomonas
aeruginosa on lung function and other clinical end points in adolescent patients with cystic …

Nebulization is a useful administration route in cystic fibrosis (CF) as it delivers antibiotics
directly to the endobronchial site of infection and is associated with decreased toxicity …

Objectives To compare the usefulness of HRCT of the chest versus spirometric measures
(PFTs) in evaluating the effect of tobramycin solution for inhalation (TSI) in cystic fibrosis …

Background. Tobramycin solution for inhalation (TOBI®; TSI) is indicated to treat patients
with cystic fibrosis who are infected with Pseudomonas aeruginosa. Preliminary findings …